Despite that at 84%, the vast majority of advisers come into contact with a client with Alzheimer's disease, only 4% of the 350 advisers polled by Fidelity Investments feel they have the tools and training necessary to help those clients.

Those concerns start at the very beginning of the problem. Half of advisers won't address with the client that they suspect Alzheimer's because they don't want to insult the client by potentially misdiagnosing benign symptoms. Advisers are also largely in the dark about many of the specific financial and legal considerations that go hand-in-hand with Alzheimer's disease.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.